This afternoon we watched Illumina rise 11.2% to a price of $118.7 per share. The Large-Cap Medical Specialities company is now trading -20.19% below its average target price of $148.73. Analysts have set target prices ranging from $100.0 to $253.0 per share for Illumina, and have given the stock an average rating of buy.
Illumina's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 3.8%. The stock's short ratio is 3.33. The company's insiders own 0.27% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 95.6%. In conclusion, we believe there is mixed market sentiment regarding Illumina.
Institutions Invested in Illumina
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 11% | 18,245,041 | $2,165,713,733 |
| 2024-03-31 | Blackrock Inc. | 9% | 13,811,060 | $1,639,393,537 |
| 2024-03-31 | State Street Corporation | 4% | 6,812,291 | $808,629,159 |
| 2024-03-31 | Edgewood Management Llc | 4% | 6,655,749 | $790,047,389 |
| 2024-03-31 | Baillie Gifford and Company | 4% | 5,736,418 | $680,921,420 |
| 2024-03-31 | Loomis Sayles & Company, LP | 3% | 4,412,277 | $523,743,898 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 3,749,045 | $445,017,264 |
| 2024-03-31 | Janus Henderson Group PLC | 2% | 3,684,585 | $437,365,766 |
| 2024-03-31 | Morgan Stanley | 2% | 3,607,967 | $428,271,094 |
| 2024-03-31 | WCM Investment Management, LLC | 2% | 3,377,221 | $400,881,198 |
